• NEBANNER

Factory wholesale Effluent Treatment - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Factory wholesale Effluent Treatment - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We always think and practice corresponding to the change of circumstance, and grow up. We purpose at the achievement of a richer mind and body as well as the living for Brackish Water Treatment, Treatment With Chemicals, Sulfur Water Treatment, The main goal of our company is to live a satisfactory memory to all the customers, and establish a long term business relationship with buyers and users all over the world.
Factory wholesale Effluent Treatment - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN Detail:

Used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

It is used to prevent or reduce the formation of thrombosis, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

The recommended dose is oral rivaroxaban 10mg, once a day. Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15mg or 20mg tablets should be taken with food.

standard: usp40
Assay: 99-102%

Exterior: White powder
Package : 25kg/drum

Take 4-(4-aminophenyl) morpholin-3-one (SM-1), (S)-N-glycidyl phthalimide (SM-2), 5-chlorothiophene-2- Formyl chloride (SM-3) is the starting material. After condensation, cyclization, aminolysis and acylation, the crude rivaroxaban is obtained, and the finished rivaroxaban is refined.
Preparation: This product is a red film-coated tablet.

Accessories:
Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate
Coating: polyethylene glycol, hypromellose, titanium dioxide, iron oxide red

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. Through highly selective and competitive inhibition of free and bound factor Xa and prothrombin activity, prolong the activated partial thromboplastin time plate (PT) and prothrombin time (aPTT) in a dose-dependent manner, which can interrupt the coagulation waterfall The endogenous and exogenous pathways inhibit the production of thrombin and thrombosis. Rivaroxaban does not inhibit thrombin (activating factor Ⅱ), nor has it proven to have an effect on platelets
The essential difference between rivaroxaban and fondaparinux/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor Xa; while heparin requires antithrombin III to function, and It has no effect on factor Xa in the prothrombin complex.


Product detail pictures:

Factory wholesale Effluent Treatment - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN detail pictures


Related Product Guide:

Our enterprise insists all along the standard policy of "product high-quality is base of business survival; client satisfaction could be the staring point and ending of an business; persistent improvement is eternal pursuit of staff" as well as consistent purpose of "reputation first, client first" for Factory wholesale Effluent Treatment - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN , The product will supply to all over the world, such as: Madrid, Lisbon, Vietnam, We have gained a lot of recognition among customers spread all across the world. They trust us and always give repetitive orders. Furthermore, mentioned below are some of the major factors that have played significant role in our tremendous growth in this domain.
  • A nice supplier in this industry, after a detail and careful discussion, we reached a consensus agreement. Hope that we cooperate smoothly.
    5 Stars By Judy from Slovakia - 2018.12.22 12:52
    A good manufacturers, we have cooperated twice, good quality and good service attitude.
    5 Stars By Kay from Sudan - 2018.06.09 12:42
    Write your message here and send it to us